{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:55Z","timestamp":1790812135140,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The effect of fibrate treatment on cardiovascular risk is inconsistent. This meta-analysis aimed to assess the effect of fibrates on major adverse cardiovascular outcome (MACE) reduction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>PubMed, Embase, and Cochrane library databases were searched up to February 2023 for randomized controlled trials comparing fibrate therapy against placebo and reporting cardiovascular outcomes and lipid profile changes. The primary outcome was the clinical outcomes of each trial that most closely corresponding to MACE, a composite of cardiovascular death, acute myocardial infarction, stroke, and coronary revascularization. A pre-specified meta-regression analysis to examine the relationship between the changes in lipid levels after fibrate treatment and the risk of MACE was also performed. Twelve trials were selected for final analysis, with 25 781 patients and 2741 MACEs in the fibrate group and 27 450 patients and 3754 MACEs in the control group. Overall, fibrate therapy was associated with decreased risk of MACE [RR 0.87, 95% confidence interval (CI) 0.81\u20130.94] with moderate heterogeneity (I2 = 47%). In meta-regression analysis, each 1\u2005mmol\/L reduction in low-density lipoprotein cholesterol (LDL-C) after fibrate treatment reduced MACE (RR 0.71, 95% CI 0.49\u20130.94, P = 0.01), while triglyceride level changes did not show a significant association (RR per 1mmol\/L reduction 0.96, 95% CI 0.53\u20131.40, P = 0.86). A sensitivity analysis with the composite outcome of cardiovascular death or acute myocardial infarction produced similar results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment with fibrates was associated with decreased risk of MACE. The reduction in MACE risk with fibrate therapy appears to be attributable to LDL-C reduction rather than a decrease in triglyceride levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwad331","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T16:52:22Z","timestamp":1697734342000},"page":"291-301","source":"Crossref","is-referenced-by-count":37,"title":["The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis"],"prefix":"10.1093","volume":"31","author":[{"given":"Kyung An","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Seoul St.Mary\u2019s Hospital, The Catholic University of Korea , 222 Banpo-daero, Seocho-gu, Seoul 06591 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Library, The Catholic University of Korea , 222 Banpo-daero, Seocho-gu, Seoul 06591 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-3176","authenticated-orcid":false,"given":"Eun Ho","family":"Choo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Seoul St.Mary\u2019s Hospital, The Catholic University of Korea , 222 Banpo-daero, Seocho-gu, Seoul 06591 , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"2024021703335978100_zwad331-B1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"2024021703335978100_zwad331-B2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"key":"2024021703335978100_zwad331-B3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators","volume":"40","author":"Oliver","year":"1978","journal-title":"Br Heart J"},{"key":"2024021703335978100_zwad331-B4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B6","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"FIELD Study Investigators","year":"2005","journal-title":"Lancet"},{"key":"2024021703335978100_zwad331-B7","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B8","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"2024021703335978100_zwad331-B10","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024021703335978100_zwad331-B11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/bmj.4.5790.767","article-title":"Five-year study by a group of physicians of the Newcastle upon Tyne region","volume":"4","author":"Trial of clofibrate in the treatment of ischaemic heart disease","year":"1971","journal-title":"Br Med J"},{"key":"2024021703335978100_zwad331-B12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/bmj.4.5790.775","article-title":"Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians","volume":"4","author":"Research Committee of the Scottish Society of P","year":"1971","journal-title":"Br Med J"},{"key":"2024021703335978100_zwad331-B13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Coronary Drug Project Research Group","year":"1975","journal-title":"JAMA"},{"key":"2024021703335978100_zwad331-B14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","author":"BIP Study Group","year":"2000","journal-title":"Circulation"},{"key":"2024021703335978100_zwad331-B15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","author":"Diabetes Atherosclerosis Intervention Study Investigators","year":"2001","journal-title":"Lancet"},{"key":"2024021703335978100_zwad331-B16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"BMJ"},{"key":"2024021703335978100_zwad331-B17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"2024021703335978100_zwad331-B18","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2024021703335978100_zwad331-B19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"2024021703335978100_zwad331-B20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.7326\/0003-4819-147-6-200709180-00007","article-title":"Changes in triglyceride levels and risk for coronary heart disease in young men","volume":"147","author":"Tirosh","year":"2007","journal-title":"Ann Intern Med"},{"key":"2024021703335978100_zwad331-B21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2024021703335978100_zwad331-B22","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B23","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Group HTRC","year":"2017","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B25","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"2024021703335978100_zwad331-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","article-title":"Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease","volume":"205","author":"Fruchart","year":"2009","journal-title":"Atherosclerosis"},{"key":"2024021703335978100_zwad331-B27","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1210\/jc.2003-030153","article-title":"Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia","volume":"88","author":"Wagner","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021703335978100_zwad331-B28","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2024021703335978100_zwad331-B29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B31","doi-asserted-by":"crossref","first-page":"101140","DOI":"10.1016\/j.plipres.2021.101140","article-title":"An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues","volume":"85","author":"Zhang","year":"2022","journal-title":"Prog Lipid Res"},{"key":"2024021703335978100_zwad331-B32","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B33","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"2024021703335978100_zwad331-B34","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/eurheartj\/ehab841","article-title":"The dawn of a new era of targeted lipid-lowering therapies","volume":"43","author":"Tokgozoglu","year":"2022","journal-title":"Eur Heart J"},{"key":"2024021703335978100_zwad331-B35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists C","year":"2012","journal-title":"Lancet"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwad331\/53970158\/zwad331.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/3\/291\/56679223\/zwad331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/3\/291\/56679223\/zwad331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T03:34:50Z","timestamp":1708140890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/31\/3\/291\/7321876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,19]]},"published-print":{"date-parts":[[2024,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwad331","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,10,19]]}}}